However, given that major peripheral blood immune subsets such as CD4+/CD8+/CD19+ can not be used as biomarkers to predict disease activation following cladribine treatment, the authors also recognize that the mechanism of action of cladribine in MS is up to debate (27). The gene discussed is CD4; the disease is myeloid sarcoma.